Kyverna Therapeutics Inc. (NASDAQ: KYTX)
$10.52
-0.5500 ( -4.97% ) 290.3K
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Market Data
Open
$10.52
Previous close
$11.07
Volume
290.3K
Market cap
$449.69M
Day range
$10.12 - $11.33
52 week range
$6.75 - $35.06
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Jul 15, 2024 |
8-k | 8K-related | 43 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 10, 2024 |
4 | Insider transactions | 1 | May 29, 2024 |
10-q | Quarterly Reports | 68 | May 14, 2024 |
8-k | 8K-related | 12 | May 14, 2024 |
10-k | Annual reports | 30 | Mar 26, 2024 |
8-k | 8K-related | 2 | Mar 26, 2024 |
4 | Insider transactions | 2 | Feb 14, 2024 |
4 | Insider transactions | 1 | Feb 14, 2024 |